Trial Profile
Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs PBF 999 (Primary)
- Indications Huntington's disease
- Focus Adverse reactions
- 21 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 May 2015 Planned End Date changed from 1 Apr 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov
- 06 May 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov